JOP20210044A1 - الأجسام المضادة لـ cd38 - Google Patents
الأجسام المضادة لـ cd38Info
- Publication number
- JOP20210044A1 JOP20210044A1 JOP/2021/0044A JOP20210044A JOP20210044A1 JO P20210044 A1 JOP20210044 A1 JO P20210044A1 JO P20210044 A JOP20210044 A JO P20210044A JO P20210044 A1 JOP20210044 A1 JO P20210044A1
- Authority
- JO
- Jordan
- Prior art keywords
- antibodies
- disclosed
- cynomolgus
- abstract
- bind
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/99—Enzyme inactivation by chemical treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
الملخص يتم الكشف عن الأجسام المضادة المعزولة التي ترتبط بـ CD38 البشري و CD38لقردة الرباح. ويتم أيضًا الكشف عن التركيبات الصيدلية المشتملة على الأجسام المضادة التي يتم الكشف عنها، وكذلك الطرق العلاجية والتشخيصية لاستخدام الأجسام المضادة التي يتم الكشف عنها.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201061428699P | 2010-12-30 | 2010-12-30 | |
US201161470406P | 2011-03-31 | 2011-03-31 | |
US201161470382P | 2011-03-31 | 2011-03-31 | |
US201161485104P | 2011-05-11 | 2011-05-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
JOP20210044A1 true JOP20210044A1 (ar) | 2017-06-16 |
Family
ID=45498158
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2021/0044A JOP20210044A1 (ar) | 2010-12-30 | 2010-12-30 | الأجسام المضادة لـ cd38 |
JOP/2011/0402A JOP20110402B1 (ar) | 2010-12-30 | 2011-12-29 | الأجسام المضادة ل cd38 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2011/0402A JOP20110402B1 (ar) | 2010-12-30 | 2011-12-29 | الأجسام المضادة ل cd38 |
Country Status (38)
Country | Link |
---|---|
US (10) | US8362211B2 (ar) |
EP (6) | EP3284755B1 (ar) |
JP (10) | JP6148984B2 (ar) |
KR (5) | KR102602640B1 (ar) |
CN (3) | CN113480649A (ar) |
AR (1) | AR084747A1 (ar) |
AU (3) | AU2011351921B2 (ar) |
BR (1) | BR112013017009B1 (ar) |
CA (1) | CA2822061C (ar) |
CO (1) | CO6761368A2 (ar) |
CR (1) | CR20130313A (ar) |
CY (3) | CY1122161T1 (ar) |
DK (3) | DK2658870T3 (ar) |
EA (2) | EA029303B1 (ar) |
EC (1) | ECSP13012794A (ar) |
ES (3) | ES2690095T3 (ar) |
GE (1) | GEP20166493B (ar) |
HK (2) | HK1245284A1 (ar) |
HR (3) | HRP20181176T1 (ar) |
HU (3) | HUE038535T2 (ar) |
IL (1) | IL226973A (ar) |
JO (2) | JOP20210044A1 (ar) |
LT (3) | LT3284754T (ar) |
MA (1) | MA34763B1 (ar) |
MX (2) | MX350903B (ar) |
MY (1) | MY160499A (ar) |
NZ (2) | NZ705848A (ar) |
PE (1) | PE20140247A1 (ar) |
PL (3) | PL3284754T3 (ar) |
PT (3) | PT2658871T (ar) |
RS (3) | RS61280B1 (ar) |
SG (1) | SG191211A1 (ar) |
SI (3) | SI3284754T1 (ar) |
TR (1) | TR201808709T4 (ar) |
TW (1) | TWI564304B (ar) |
UY (1) | UY33850A (ar) |
WO (2) | WO2012092612A1 (ar) |
ZA (1) | ZA201304696B (ar) |
Families Citing this family (183)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2555185C (en) | 2004-02-06 | 2020-03-24 | Morphosys Ag | Anti-cd38 human antibodies and uses therefor |
US9200061B2 (en) * | 2004-02-06 | 2015-12-01 | Morpho Sys AG | Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i |
HUE035250T2 (hu) | 2005-10-12 | 2018-05-02 | Morphosys Ag | Humán CD38-ra specifikus teljesen humán HuCAL GOLD-eredetû terápiás ellenanyagok létrehozása és profilozása |
EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
HUE031956T2 (en) | 2010-09-27 | 2017-08-28 | Morphosys Ag | Anti-CD38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and NHL |
JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
CN109022465B (zh) | 2011-10-28 | 2022-04-29 | 特瓦制药澳大利亚私人有限公司 | 多肽构建体及其用途 |
EP2873422A4 (en) | 2012-07-10 | 2015-12-30 | Takeda Pharmaceutical | PHARMACEUTICAL PREPARATION FOR INJECTION |
MX368288B (es) | 2012-09-25 | 2019-09-27 | Morphosys Ag | Una combinación de anticuerpos anti-cd38 y melfalán para usarse en el tratamiento de mieloma múltiple. |
US10342869B2 (en) | 2012-12-07 | 2019-07-09 | The Regents Of The University Of California | Compositions comprising anti-CD38 antibodies and lenalidomide |
UA118255C2 (uk) * | 2012-12-07 | 2018-12-26 | Санофі | Композиція, яка містить антитіло до cd38 і леналідомід |
CA3071678A1 (en) * | 2013-04-16 | 2014-10-23 | Genentech,Inc. | Pertuzumab variants and evaluation thereof |
ES2774976T3 (es) * | 2013-04-29 | 2020-07-23 | Teva Pharmaceuticals Australia Pty Ltd | Anticuerpos anti-CD38 y fusiones con interferón alfa-2b atenuado |
US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
US20150118251A1 (en) * | 2013-10-31 | 2015-04-30 | Sanofi | Specific anti-cd38 antibodies for treating human cancers |
SG10201909806SA (en) | 2013-11-04 | 2019-11-28 | Glenmark Pharmaceuticals Sa | Production of t cell retargeting hetero-dimeric immunoglobulins |
JP2017506640A (ja) * | 2014-02-14 | 2017-03-09 | セントローズ, エルエルシー | 細胞外標的化薬物共役体 |
US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
US9732154B2 (en) * | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
US20170335281A1 (en) | 2014-03-15 | 2017-11-23 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
UA119352C2 (uk) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
US10738278B2 (en) | 2014-07-15 | 2020-08-11 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
JP2017528433A (ja) | 2014-07-21 | 2017-09-28 | ノバルティス アーゲー | 低い免疫増強用量のmTOR阻害剤とCARの組み合わせ |
ES2890669T3 (es) | 2014-09-09 | 2022-01-21 | Janssen Biotech Inc | Terapias de combinación con anticuerpos anti-CD38 |
CA2965414C (en) | 2014-10-29 | 2024-01-09 | Teva Pharmaceuticals Australia Pty Ltd | Interferon .alpha.2.beta. variants |
MA40894A (fr) * | 2014-11-04 | 2017-09-12 | Glenmark Pharmaceuticals Sa | Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production |
US11773166B2 (en) | 2014-11-04 | 2023-10-03 | Ichnos Sciences SA | CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production |
KR102597989B1 (ko) * | 2014-12-04 | 2023-11-02 | 얀센 바이오테크 인코포레이티드 | 급성 골수성 백혈병을 치료하기 위한 항-cd38 항체 |
US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
MA41555A (fr) * | 2015-02-17 | 2017-12-26 | Millennium Pharm Inc | Polythérapie pour le traitement du cancer |
WO2016164656A1 (en) | 2015-04-08 | 2016-10-13 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind cd38 |
EP3286211A1 (en) | 2015-04-23 | 2018-02-28 | Novartis AG | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
US10766965B2 (en) * | 2015-05-20 | 2020-09-08 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of light chain amyloidosis and other CD38-positive hematological malignancies |
IL292708B1 (en) | 2015-05-30 | 2024-04-01 | Molecular Templates Inc | Vaccine-free Shiga toxin A subunit scaffolds and cell-targeting molecules containing them |
CR20170587A (es) | 2015-06-22 | 2018-04-03 | Janssen Biotech Inc | Terapias de combinación para enfermedades malignas hematológicas con anticuerpos anti-cd38 e inhibidores de survivina |
US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
BR112017027990A2 (pt) | 2015-06-24 | 2018-08-28 | Janssen Biotech, Inc. | modulação imune e tratamento de tumores sólidos com anticorpos que se ligam especificamente ao cd38 |
UA124616C2 (uk) | 2015-07-06 | 2021-10-20 | Юсб Біофарма Срл | Зв'язуюче тау-білок антитіло |
MA42895A (fr) | 2015-07-15 | 2018-05-23 | Juno Therapeutics Inc | Cellules modifiées pour thérapie cellulaire adoptive |
WO2017027392A1 (en) | 2015-08-07 | 2017-02-16 | Novartis Ag | Treatment of cancer using chimeric cd3 receptor proteins |
WO2017058850A1 (en) | 2015-09-28 | 2017-04-06 | Regents Of The University Of Minnesota | Chimeric antigen receptor (car) t cells as therapeutic interventions for auto- and allo-immunity |
AU2016347058B2 (en) | 2015-10-25 | 2023-11-09 | Sanofi | Trispecific and/or trivalent binding proteins for prevention or treatment of HIV infection |
WO2017079150A1 (en) | 2015-11-03 | 2017-05-11 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-cd38 antibodies and their uses |
US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
EP3380620A1 (en) | 2015-11-23 | 2018-10-03 | Novartis AG | Optimized lentiviral transfer vectors and uses thereof |
EP3397756B1 (en) | 2015-12-30 | 2023-03-08 | Novartis AG | Immune effector cell therapies with enhanced efficacy |
CN105546709B (zh) * | 2016-02-04 | 2019-01-04 | 山东格瑞德集团有限公司 | 孔板送风布风系统 |
EP3423498A1 (en) * | 2016-03-04 | 2019-01-09 | MorphoSys AG | Clinical assessment of m-protein response in multiple myeloma |
US11549099B2 (en) | 2016-03-23 | 2023-01-10 | Novartis Ag | Cell secreted minibodies and uses thereof |
SG11201808911SA (en) | 2016-04-13 | 2018-11-29 | Sanofi Sa | Trispecific and/or trivalent binding proteins |
DK3443006T5 (da) | 2016-04-13 | 2023-11-06 | Sanofi Sa | Trispecifikke og/eller trivalente bindingsproteiner |
EP3452109A1 (en) * | 2016-05-03 | 2019-03-13 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Cd31shed as a molecular target for imaging of inflammation |
JP2019527678A (ja) * | 2016-06-28 | 2019-10-03 | ユーエムセー・ユトレヒト・ホールディング・ベー・フェー | CD38に特異的に結合する抗体によるIgE媒介疾患の治療 |
EP3484923A1 (en) | 2016-07-15 | 2019-05-22 | Takeda Pharmaceutical Company Limited | Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies |
CN110087673A (zh) | 2016-07-19 | 2019-08-02 | 梯瓦制药澳大利亚股份有限公司 | 抗cd47联合治疗 |
WO2018015498A1 (en) | 2016-07-20 | 2018-01-25 | Hybrigenics Sa | Combinations of inecalcitol with an anti-cd38 agent and their uses for treating cancer |
EP4295918A3 (en) | 2016-11-02 | 2024-03-20 | Bristol-Myers Squibb Company | Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma |
EP3535585A1 (en) * | 2016-11-04 | 2019-09-11 | Aarhus Universitet | Identification and treatment of tumors characterized by an overexpression of the neonatal fc receptor |
WO2018111340A1 (en) | 2016-12-16 | 2018-06-21 | Novartis Ag | Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells |
ES2912408T3 (es) | 2017-01-26 | 2022-05-25 | Novartis Ag | Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos |
WO2018144535A1 (en) | 2017-01-31 | 2018-08-09 | Novartis Ag | Treatment of cancer using chimeric t cell receptor proteins having multiple specificities |
EP3589647A1 (en) | 2017-02-28 | 2020-01-08 | Novartis AG | Shp inhibitor compositions and uses for chimeric antigen receptor therapy |
EP3597217A4 (en) * | 2017-03-01 | 2021-01-13 | Institute for Rheumatic Diseases Co., Ltd. | PROPHYLACTIC AND / OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE AND VACCINE |
EP3604340A4 (en) | 2017-03-24 | 2021-01-06 | Zenyaku Kogyo Co., Ltd | ANTI-IGM / B-CELL SURFACE ANTIGEN-BISPECIFIC ANTIBODY |
US11104737B2 (en) | 2017-03-28 | 2021-08-31 | Rigel Pharmaceuticals, Inc. | ACVR2A-specific antibody and method of treatment of muscle atrophy |
EP3610022A1 (en) | 2017-04-14 | 2020-02-19 | Tollnine, Inc. | Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use |
CN117534754A (zh) | 2017-06-08 | 2024-02-09 | 黑带医疗有限公司 | Cd38调节抗体 |
KR20200021069A (ko) * | 2017-06-08 | 2020-02-27 | 블랙 벨트 테라퓨틱스 리미티드 | Cd38 조정 항체 |
WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
CN114350613A (zh) | 2017-06-20 | 2022-04-15 | 居里研究所 | Suv39h1缺陷的免疫细胞 |
JP7359700B2 (ja) * | 2017-06-20 | 2023-10-11 | ソレント・セラピューティクス・インコーポレイテッド | Cd38抗体薬物コンジュゲート |
EP3434692A1 (en) * | 2017-07-24 | 2019-01-30 | Encefa | Compounds which specifically binds to cd38 for use in the treatment of neurodegenerative diseases |
WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
WO2019034752A1 (en) * | 2017-08-16 | 2019-02-21 | Tusk Therapeutics Ltd | CD38 MODULATOR ANTIBODY |
AU2018316522A1 (en) | 2017-08-16 | 2020-03-05 | Black Belt Therapeutics Limited | CD38 antibody |
US11542338B2 (en) | 2017-08-16 | 2023-01-03 | Black Belt Therapeutics Limited | CD38 modulating antibody |
CN111133007A (zh) | 2017-09-13 | 2020-05-08 | 特尼奥生物股份有限公司 | 与胞外酶结合的重链抗体 |
CN111788225A (zh) * | 2017-10-10 | 2020-10-16 | 赛诺菲 | 抗cd38抗体及与抗cd3和抗cd28抗体的组合 |
MX2020004229A (es) | 2017-10-25 | 2020-07-22 | Novartis Ag | Metodos de produccion de celulas que expresan receptores antigenicos quimericos. |
WO2019081983A1 (en) | 2017-10-25 | 2019-05-02 | Novartis Ag | CD32B TARGETING ANTIBODIES AND METHODS OF USE |
AU2018359527A1 (en) | 2017-10-31 | 2020-05-07 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
US20210179709A1 (en) | 2017-10-31 | 2021-06-17 | Novartis Ag | Anti-car compositions and methods |
MX2020004240A (es) | 2017-11-01 | 2020-09-25 | Juno Therapeutics Inc | Proceso para generar composiciones terapeuticas de celulas modificadas. |
MX2020004572A (es) | 2017-11-01 | 2020-10-07 | Juno Therapeutics Inc | Receptores de antigenos quimericos especificos para el antigeno de maduracion de celulas b y polinucleotidos que codifican los mismos. |
US11564946B2 (en) | 2017-11-01 | 2023-01-31 | Juno Therapeutics, Inc. | Methods associated with tumor burden for assessing response to a cell therapy |
EP3704229B1 (en) | 2017-11-01 | 2023-12-20 | Juno Therapeutics, Inc. | Process for producing a t cell composition |
US20210132042A1 (en) | 2017-11-01 | 2021-05-06 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
KR20200074997A (ko) | 2017-11-01 | 2020-06-25 | 주노 쎄러퓨티크스 인코퍼레이티드 | B-세포 성숙 항원에 특이적인 항체 및 키메릭 항원 수용체 |
WO2019087151A1 (en) | 2017-11-03 | 2019-05-09 | Sorrento Therapeutics, Inc. | Cd38-directed chimeric antigen receptor constructs |
JP7402158B2 (ja) * | 2017-11-30 | 2023-12-20 | ジェネンテック, インコーポレイテッド | 抗pd-l1抗体及びpd-l1を検出するためにそれを使用する方法 |
ES2949855T3 (es) * | 2017-12-05 | 2023-10-03 | Medical Res Infrastructure & Health Services Fund Tel Aviv Medical Ct | Linfocitos T que comprenden receptores antigénicos quiméricos anti-CD38 y ant-CD138 y los usos de los mismos |
JP2021505168A (ja) | 2017-12-08 | 2021-02-18 | ジュノー セラピューティクス インコーポレイテッド | 操作されたt細胞の組成物を製造するための方法 |
EP3720480A2 (en) | 2017-12-08 | 2020-10-14 | Juno Therapeutics, Inc. | Phenotypic markers for cell therapy and related methods |
CN112041430A (zh) | 2017-12-08 | 2020-12-04 | 朱诺治疗学股份有限公司 | 用于培养细胞的无血清培养基配制品及其使用方法 |
EP3737702A1 (en) * | 2018-01-12 | 2020-11-18 | Takeda Pharmaceutical Company Limited | Subcutaneous dosing of anti-cd38 antibodies |
CN110144008B (zh) * | 2018-02-12 | 2021-03-19 | 杭州尚健生物技术有限公司 | Cd38蛋白抗体及其应用 |
BR112020019710A2 (pt) * | 2018-03-28 | 2021-01-26 | Takeda Pharmaceutical Company Limited | métodos para tratar uma doença em um sujeito e para tratar um câncer hematológico em um sujeito, e, forma farmacêutica unitária. |
CN108318689A (zh) * | 2018-04-09 | 2018-07-24 | 北京大学深圳研究生院 | 一种多发性骨髓瘤的诊断方法 |
US20210047405A1 (en) | 2018-04-27 | 2021-02-18 | Novartis Ag | Car t cell therapies with enhanced efficacy |
EP3788369A1 (en) | 2018-05-01 | 2021-03-10 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
WO2019227003A1 (en) | 2018-05-25 | 2019-11-28 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
WO2019237035A1 (en) | 2018-06-08 | 2019-12-12 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
CN108752475B (zh) * | 2018-06-14 | 2021-07-30 | 北京智仁美博生物科技有限公司 | 抗人cd38抗体及其用途 |
AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
WO2020012038A1 (en) | 2018-07-13 | 2020-01-16 | Genmab A/S | Trogocytosis-mediated therapy using cd38 antibodies |
TW202019518A (zh) | 2018-07-13 | 2020-06-01 | 丹麥商珍美寶股份有限公司 | Cd38抗體之變體及其用途 |
SG11202101130VA (en) | 2018-08-09 | 2021-03-30 | Juno Therapeutics Inc | Methods for assessing integrated nucleic acids |
AU2019338999A1 (en) | 2018-09-11 | 2021-03-18 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-CD38 antibody, antigen-binding fragment thereof, and pharmaceutical use |
CN109053892B (zh) | 2018-09-19 | 2021-03-26 | 苏州思坦维生物技术股份有限公司 | 特异结合人及猴cd38抗原的单克隆抗体及其制备方法与应用 |
SG11202103478RA (en) | 2018-10-09 | 2021-05-28 | Sanofi Sa | Trispecific anti-cd38, anti-cd28, and anti-cd3 binding proteins and methods of use for treating viral infection |
WO2020087065A1 (en) | 2018-10-26 | 2020-04-30 | Teneobio, Inc. | Heavy chain antibodies binding to cd38 |
EP3873943A2 (en) | 2018-11-01 | 2021-09-08 | Juno Therapeutics, Inc. | Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen |
PE20211058A1 (es) | 2018-11-01 | 2021-06-07 | Juno Therapeutics Inc | Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d) |
US20220110872A1 (en) | 2018-12-14 | 2022-04-14 | Morphosys Ag | Antibody formulations |
CA3123511A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
KR20210119448A (ko) * | 2019-01-23 | 2021-10-05 | 앙세파 | Cd31 경쟁인자(competitor) 및 이의 용도 |
US11414496B2 (en) | 2019-01-23 | 2022-08-16 | Takeda Pharmaceutical Company Limited | Anti-CD38 binding domains |
EP3914610A1 (en) | 2019-01-23 | 2021-12-01 | Millennium Pharmaceuticals, Inc. | Cd38-binding proteins comprising de-immunized shiga toxin a subunit effectors |
CA3123519A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
WO2020165833A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
CN113574071A (zh) | 2019-03-15 | 2021-10-29 | 莫佛塞斯公司 | 用于治疗自身抗体介导的自身免疫疾病的抗-cd38抗体及其药物组合物 |
WO2020194242A1 (en) * | 2019-03-28 | 2020-10-01 | Janssen Biotech, Inc. | Clinically proven subcutaneous pharmaceutical compositions comprising anti-cd38 antibodies and their uses in combination with pomalidomide and dexamethasone |
US20200316197A1 (en) * | 2019-03-28 | 2020-10-08 | Janssen Biotech, Inc. | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib and Dexamethasone |
WO2020194243A1 (en) * | 2019-03-28 | 2020-10-01 | Janssen Biotech, Inc. | Clinically proven subcutaneous pharmaceutical compositions comprising anti-cd38 antibodies and their uses in combination with lenalidomide and dexamethasone |
WO2020194245A1 (en) * | 2019-03-28 | 2020-10-01 | Janssen Biotech, Inc. | Clinically proven subcutaneous pharmaceutical compositions comprising anti-cd38 antibodies and their uses in combination with bortezomib, melphalan and prednisone |
JP2022527084A (ja) * | 2019-03-29 | 2022-05-30 | ソレント・セラピューティクス・インコーポレイテッド | Cd38に結合する操作されたバリアント抗体 |
US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
EP3953388A1 (en) * | 2019-04-09 | 2022-02-16 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
BR112021021200A2 (pt) | 2019-05-01 | 2021-12-21 | Juno Therapeutics Inc | Células expressando um receptor quimérico de um locus cd247 modificado, polinucleotídeos relacionados e métodos |
BR112021021075A2 (pt) | 2019-05-01 | 2021-12-14 | Editas Medicine Inc | Células que expressam um receptor recombinante de um locus de tgfbr2 modificado, polinucleotídeos relacionados e métodos |
CN113993543A (zh) | 2019-06-10 | 2022-01-28 | 武田药品工业株式会社 | 使用抗cd38抗体的组合疗法 |
CN114269372A (zh) | 2019-06-27 | 2022-04-01 | 克里斯珀医疗股份公司 | 嵌合抗原受体t细胞和nk细胞抑制剂用于治疗癌症的用途 |
WO2021003074A1 (en) * | 2019-07-03 | 2021-01-07 | Crystal Bioscience Inc. | Anti-cd38 antibody and methods of use thereof |
CN114222815A (zh) | 2019-07-23 | 2022-03-22 | 记忆疗法公司 | Suv39h1缺陷的免疫细胞 |
CN112538114A (zh) * | 2019-09-20 | 2021-03-23 | 上海普铭生物科技有限公司 | 抗人cd38抗体及其应用 |
US20220387317A1 (en) * | 2019-11-07 | 2022-12-08 | Ohio State Innovation Foundation | Methods and compositions relating to selective intracellular delivery of cd38 inhibitors |
CN112876563B (zh) * | 2019-11-29 | 2022-08-16 | 康诺亚生物医药科技(成都)有限公司 | 药物组合物及其制备方法和应用 |
JP2023507120A (ja) | 2019-12-18 | 2023-02-21 | テネオフォー, インコーポレイテッド | Cd38に結合する重鎖抗体 |
CN115175937A (zh) | 2019-12-20 | 2022-10-11 | 诺华股份有限公司 | 用于治疗骨髓纤维化和骨髓增生异常综合征的抗TIM-3抗体MBG453和抗TGF-β抗体NIS793与或不与地西他滨或抗PD-1抗体斯巴达珠单抗的组合 |
KR20220130724A (ko) | 2020-01-16 | 2022-09-27 | 젠맵 에이/에스 | Cd38 항체의 제제 및 그의 용도 |
US11920136B2 (en) | 2020-02-28 | 2024-03-05 | Tallac Therapeutics, Inc. | Transglutaminase-mediated conjugation |
IL296723A (en) | 2020-03-26 | 2022-11-01 | Seagen Inc | Treatment methods for multiple myeloma |
BR112022020333A2 (pt) | 2020-04-10 | 2022-11-22 | Juno Therapeutics Inc | Métodos e usos relacionados à terapia celular projetada com um receptor de antígeno quimérico que alveja o antígeno de maturação de células b |
WO2021226584A1 (en) * | 2020-05-08 | 2021-11-11 | University Of Southern California | Site-specific antibody-drug conjugates by adp-ribosyl cyclases |
US20230178239A1 (en) | 2020-05-13 | 2023-06-08 | Juno Therapeutics, Inc. | Methods of identifying features associated with clinical response and uses thereof |
JP2023529211A (ja) | 2020-06-11 | 2023-07-07 | ノバルティス アーゲー | Zbtb32阻害剤及びその使用 |
JP2023531676A (ja) | 2020-06-23 | 2023-07-25 | ノバルティス アーゲー | 3-(1-オキソイソインドリン-2-イル)ピぺリジン-2,6-ジオン誘導体を含む投与レジメン |
WO2021260657A1 (en) | 2020-06-26 | 2021-12-30 | Crispr Therapeutics Ag | Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 |
EP4171616A1 (en) | 2020-06-26 | 2023-05-03 | Juno Therapeutics GmbH | Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods |
JP2023535501A (ja) | 2020-07-30 | 2023-08-17 | アンスティテュ・クリー | Socs1に欠陥のある免疫細胞 |
WO2022029573A1 (en) | 2020-08-03 | 2022-02-10 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
US20230398148A1 (en) | 2020-11-04 | 2023-12-14 | Juno Therapeutics, Inc. | Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods |
JP2024508207A (ja) | 2020-12-02 | 2024-02-26 | ブイアイビー ブイゼットダブリュ | がんに対する組み合わせ治療におけるltbrアゴニスト |
WO2022137186A1 (en) | 2020-12-23 | 2022-06-30 | Crispr Therapeutics Ag | Cancer treatment using cd38 inhibitor and/or lenalidomide and t-cells expressing a chimeric antigen receptor |
KR20230165771A (ko) | 2021-03-03 | 2023-12-05 | 주노 쎄러퓨티크스 인코퍼레이티드 | T 세포 요법 및 dgk 억제제의 조합 |
CA3212343A1 (en) | 2021-03-17 | 2022-09-22 | Kazunori YOSHIKIYO | Gene encoding a chimeric receptor for an anti-acetylcholine receptor autoantibody |
TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途 |
CN118056008A (zh) | 2021-04-27 | 2024-05-17 | 诺华股份有限公司 | 病毒载体生产系统 |
CN117916256A (zh) | 2021-05-06 | 2024-04-19 | 朱诺治疗学有限公司 | 用于刺激和转导t细胞的方法 |
WO2022238386A1 (en) | 2021-05-10 | 2022-11-17 | Institut Curie | Methods for the treatment of cancer, inflammatory diseases and autoimmune diseases |
TW202310870A (zh) | 2021-05-12 | 2023-03-16 | 瑞士商Crispr治療公司 | 用於治療造血惡性腫瘤之靶向cd70的基因工程化免疫細胞 |
WO2022238963A2 (en) | 2021-05-12 | 2022-11-17 | Crispr Therapeutics Ag | Genetically engineered immune cells targeting cd70 for use in treating solid tumors |
WO2022242892A1 (en) * | 2021-05-17 | 2022-11-24 | Université de Liège | Anti-cd38 single-domain antibodies in disease monitoring and treatment |
EP4346912A1 (en) | 2021-05-25 | 2024-04-10 | Institut Curie | Myeloid cells overexpressing bcl2 |
WO2022271987A1 (en) | 2021-06-23 | 2022-12-29 | TeneoFour, Inc. | Anti-cd38 antibodies and epitopes of same |
IL310372A (en) | 2021-07-28 | 2024-03-01 | Genentech Inc | IL15/IL15R alpha heterodimeric FC-fused proteins for the treatment of blood cancer |
WO2023017392A1 (en) | 2021-08-13 | 2023-02-16 | 3M Innovative Properties Company | Antistatic fabric article |
CN113896802A (zh) * | 2021-10-09 | 2022-01-07 | 宜明昂科生物医药技术(上海)有限公司 | 靶向cd47和cd38的重组融合蛋白及其制备和用途 |
WO2023126458A1 (en) | 2021-12-28 | 2023-07-06 | Mnemo Therapeutics | Immune cells with inactivated suv39h1 and modified tcr |
WO2023147515A1 (en) | 2022-01-28 | 2023-08-03 | Juno Therapeutics, Inc. | Methods of manufacturing cellular compositions |
TW202342520A (zh) | 2022-02-18 | 2023-11-01 | 美商樂天醫藥生技股份有限公司 | 抗計畫性死亡配體1(pd—l1)抗體分子、編碼多核苷酸及使用方法 |
WO2023187024A1 (en) | 2022-03-31 | 2023-10-05 | Institut Curie | Modified rela protein for inducing interferon expression and engineered immune cells with improved interferon expression |
WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
WO2023213969A1 (en) | 2022-05-05 | 2023-11-09 | Juno Therapeutics Gmbh | Viral-binding protein and related reagents, articles, and methods of use |
WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
WO2023230548A1 (en) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Method for predicting response to a t cell therapy |
WO2023230581A1 (en) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Methods of manufacturing t cell therapies |
WO2024054944A1 (en) | 2022-09-08 | 2024-03-14 | Juno Therapeutics, Inc. | Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing |
WO2024054775A1 (en) * | 2022-09-09 | 2024-03-14 | Takeda Pharmaceutical Company Limited | Subcutaneous dosing of anti-cd38 antibodies for treating patients with moderate to severe systemic lupus erythematosus |
WO2024079010A1 (en) | 2022-10-10 | 2024-04-18 | F. Hoffmann-La Roche Ag | Combination therapy of a gprc5d tcb and cd38 antibodies |
WO2024089639A1 (en) | 2022-10-26 | 2024-05-02 | Novartis Ag | Lentiviral formulations |
WO2024094660A1 (en) | 2022-10-31 | 2024-05-10 | Genmab A/S | Cd38 antibodies and uses thereof |
WO2024100604A1 (en) | 2022-11-09 | 2024-05-16 | Juno Therapeutics Gmbh | Methods for manufacturing engineered immune cells |
Family Cites Families (135)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
US4169888A (en) | 1977-10-17 | 1979-10-02 | The Upjohn Company | Composition of matter and process |
US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US4970198A (en) | 1985-10-17 | 1990-11-13 | American Cyanamid Company | Antitumor antibiotics (LL-E33288 complex) |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
DE3783588T2 (de) | 1986-04-17 | 1993-06-09 | Kyowa Hakko Kogyo Kk | Neue verbindungen dc-88a und dc-89a1 und deren herstellungsverfahren. |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
US5053394A (en) | 1988-09-21 | 1991-10-01 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
IL89220A (en) | 1988-02-11 | 1994-02-27 | Bristol Myers Squibb Co | Immunoconjugates of anthracycline, their production and pharmaceutical preparations containing them |
US5084468A (en) | 1988-08-11 | 1992-01-28 | Kyowa Hakko Kogyo Co., Ltd. | Dc-88a derivatives |
JP2598116B2 (ja) | 1988-12-28 | 1997-04-09 | 協和醗酵工業株式会社 | 新規物質dc113 |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
JP2510335B2 (ja) | 1989-07-03 | 1996-06-26 | 協和醗酵工業株式会社 | Dc―88a誘導体 |
US5187186A (en) | 1989-07-03 | 1993-02-16 | Kyowa Hakko Kogyo Co., Ltd. | Pyrroloindole derivatives |
CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
EP0530225A4 (en) | 1990-05-07 | 1993-09-22 | Scripps Clinic And Research Foundation | Intermediates in the formation of the calicheamicin and esperamicin oligosaccharides |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
US5264586A (en) | 1991-07-17 | 1993-11-23 | The Scripps Research Institute | Analogs of calicheamicin gamma1I, method of making and using the same |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
ES2149768T3 (es) | 1992-03-25 | 2000-11-16 | Immunogen Inc | Conjugados de agentes enlazantes de celulas derivados de cc-1065. |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
WO1994013804A1 (en) | 1992-12-04 | 1994-06-23 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
WO1994017184A1 (en) * | 1993-01-29 | 1994-08-04 | Schering Corporation | Modulation of physiological responses of lymphocytes by cd38 or antibodies thereto |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
AU689131B2 (en) | 1993-10-01 | 1998-03-26 | Teikoku Hormone Mfg. Co., Ltd. | Novel peptide derivative |
ATE271557T1 (de) | 1994-04-22 | 2004-08-15 | Kyowa Hakko Kogyo Kk | Dc-89 derivat |
JPH07309761A (ja) | 1994-05-20 | 1995-11-28 | Kyowa Hakko Kogyo Co Ltd | デュオカルマイシン誘導体の安定化法 |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
US5550246A (en) | 1994-09-07 | 1996-08-27 | The Scripps Research Institute | Calicheamicin mimics |
US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
US6086875A (en) | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
PT871490E (pt) | 1995-12-22 | 2003-07-31 | Bristol Myers Squibb Co | Ligantes de hidrazona ramificada |
ES2236634T3 (es) | 1997-04-07 | 2005-07-16 | Genentech, Inc. | Anticuerpos anti-vegf. |
DK2180007T4 (da) | 1998-04-20 | 2017-11-27 | Roche Glycart Ag | Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet |
US7112661B1 (en) | 1998-10-30 | 2006-09-26 | The Research Foundation Of State University Of New York | Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein Ib alpha |
US7425541B2 (en) | 1998-12-11 | 2008-09-16 | Medarex, Inc. | Enzyme-cleavable prodrug compounds |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
US6939545B2 (en) | 1999-04-28 | 2005-09-06 | Genetics Institute, Llc | Composition and method for treating inflammatory disorders |
CA2385528C (en) | 1999-10-01 | 2013-12-10 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
US7303749B1 (en) | 1999-10-01 | 2007-12-04 | Immunogen Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
JP4668498B2 (ja) | 1999-10-19 | 2011-04-13 | 協和発酵キリン株式会社 | ポリペプチドの製造方法 |
US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
MXPA03002974A (es) | 2000-10-06 | 2004-05-05 | Kyowa Hakko Kogyo Kk | Celulas que producen composiciones de anticuerpo. |
CA2424977C (en) | 2000-10-06 | 2008-03-18 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
IT1320715B1 (it) | 2000-10-19 | 2003-12-10 | Cselt Centro Studi Lab Telecom | Modulo generatore di circuiti per la decodifica di codiciconvoluzionali, metodo per la generazione di tale tipo di circuito e |
EP2357187A1 (en) | 2000-12-12 | 2011-08-17 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
CN101508734A (zh) * | 2001-04-27 | 2009-08-19 | 协和发酵麒麟株式会社 | 抗cd40单克隆抗体 |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
EP1434778A4 (en) | 2001-05-31 | 2005-07-13 | Medarex Inc | CYTOTOXINS, PROMEDICAMENTS, BINDERS AND STABILIZERS USEFUL THEREFOR |
US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
AU2002368077B2 (en) | 2001-07-12 | 2010-03-04 | Jefferson Foote | Super humanized antibodies |
JP4166691B2 (ja) | 2001-08-03 | 2008-10-15 | タイコ ヘルスケア グループ エルピー | 組織マーキング装置および方法 |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
ES2556641T3 (es) | 2002-07-31 | 2016-01-19 | Seattle Genetics, Inc. | Conjugados de fármacos y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa |
EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
US20060235208A1 (en) | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
DE10246870B3 (de) | 2002-10-08 | 2004-04-29 | Renk Aktiengesellschaft | Elektro-Hydrodynamische Überlagerungslenkung |
CN100526460C (zh) * | 2002-11-08 | 2009-08-12 | 麒麟医药株式会社 | 朊病毒蛋白活性降低的转基因有蹄类动物及其用途 |
EP1560599A1 (en) | 2002-11-14 | 2005-08-10 | Syntarga B.V. | Prodrugs built as multiple self-elimination-release spacers |
US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
US7610156B2 (en) | 2003-03-31 | 2009-10-27 | Xencor, Inc. | Methods for rational pegylation of proteins |
US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
BRPI0410748B8 (pt) | 2003-05-20 | 2021-05-25 | Immunogen Inc | compostos de maitansinóides, suas composições farmacêuticas, métodos de esterificação de maitansinóides, bem como métodos para a sua produção, e conjugado de maitansinóide-agente de ligação celular |
SG195524A1 (en) | 2003-11-06 | 2013-12-30 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
WO2005082023A2 (en) | 2004-02-23 | 2005-09-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
ES2533695T3 (es) | 2004-03-02 | 2015-04-14 | Seattle Genetics, Inc. | Anticuerpos cargados parcialmente y métodos para su conjugación |
NZ550934A (en) | 2004-05-19 | 2010-05-28 | Medarex Inc | Chemical linkers and conjugates thereof |
US7691962B2 (en) | 2004-05-19 | 2010-04-06 | Medarex, Inc. | Chemical linkers and conjugates thereof |
AU2005286607B2 (en) | 2004-09-23 | 2011-01-27 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
EP3312196B1 (en) * | 2005-03-23 | 2019-07-17 | Genmab A/S | Antibodies against cd38 for treatment of multiple myeloma |
US7714016B2 (en) | 2005-04-08 | 2010-05-11 | Medarex, Inc. | Cytotoxic compounds and conjugates with cleavable substrates |
CA2605507C (en) | 2005-04-19 | 2016-06-28 | Seattle Genetics, Inc. | Humanized anti-cd70 binding agents and uses thereof |
EP2799451A1 (en) * | 2005-05-24 | 2014-11-05 | MorphoSys AG | Generation and profiling of fully human HuCAL GOLD®-derived therapeutic antibodies specific for human CD38 |
EP4026840A1 (en) | 2005-07-18 | 2022-07-13 | Seagen Inc. | Beta-glucuronide-linker drug conjugates |
EP1909846B1 (en) | 2005-08-05 | 2018-12-26 | Syntarga B.V. | Triazole-containing releasable linkers, conjugates comprising the same and processes for their preparation |
AU2006299429B2 (en) | 2005-10-03 | 2012-02-23 | Xencor, Inc. | Fc variants with optimized Fc receptor binding properties |
HUE035250T2 (hu) | 2005-10-12 | 2018-05-02 | Morphosys Ag | Humán CD38-ra specifikus teljesen humán HuCAL GOLD-eredetû terápiás ellenanyagok létrehozása és profilozása |
AU2006305842B2 (en) | 2005-10-26 | 2011-11-03 | E. R. Squibb & Sons, L.L.C. | Methods and compounds for preparing CC-1065 analogs |
WO2007059404A2 (en) | 2005-11-10 | 2007-05-24 | Medarex, Inc. | Duocarmycin derivatives as novel cytotoxic compounds and conjugates |
MX2008009956A (es) | 2006-02-02 | 2008-12-12 | Syntarga Bv | Analogos de cc-1065 solubles en agua y sus conjugados. |
EP2078732B1 (en) | 2006-07-10 | 2015-09-16 | Fujita Health University | Method of identifying a candidate diagnostic or therapeutic antibody using flow cytometry |
TR201910145T4 (tr) | 2006-09-26 | 2019-08-21 | Genmab As | Tümörlerin tedavi edilmesine yönelik anti-CD38 artı kortikosteroidler artı bir kortikosteroid-olmayan kemoterapötik. |
EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
EP2173739B1 (en) | 2007-08-01 | 2013-07-31 | Syntarga B.V. | Substituted cc-1065 analogs and their conjugates |
US20090076249A1 (en) | 2007-09-19 | 2009-03-19 | Michel De Weers | Antibodies against CD38 for treatment of multiple myeloma |
RU2570559C2 (ru) * | 2007-12-17 | 2015-12-10 | Пфайзер Лимитед | Лечение интерстициального цистита |
US8399630B2 (en) * | 2008-08-20 | 2013-03-19 | Centocor Ortho Biotech Inc. | Engineered anti-IL-13 antibodies, compositions, methods and uses |
ES2647317T3 (es) | 2008-11-03 | 2017-12-20 | Syntarga B.V. | Análogos de CC-1065 y sus conjugados |
EP2191840A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan |
EP2191841A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine |
EP2191842A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine |
EP2191843A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide |
EP2412808B1 (en) | 2009-03-25 | 2016-09-07 | Tohoku University | Lh-type bispecific antibody |
US10817851B2 (en) | 2009-12-23 | 2020-10-27 | Aristocrat Technologies Australia Pty Limited | System and method for cashless gaming |
UA112170C2 (uk) | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
US11392902B2 (en) | 2017-06-06 | 2022-07-19 | United Parcel Service Of America, Inc. | Systems, methods, apparatuses and computer program products for providing notification of items for pickup and delivery |
CN113194990A (zh) * | 2018-07-11 | 2021-07-30 | 动量制药公司 | 与靶向CD38的工程化Fc-抗原结合结构域构建体有关的组合物和方法 |
-
2010
- 2010-12-30 JO JOP/2021/0044A patent/JOP20210044A1/ar unknown
-
2011
- 2011-12-29 TW TW100149611A patent/TWI564304B/zh active
- 2011-12-29 AR ARP110105024A patent/AR084747A1/es active IP Right Grant
- 2011-12-29 JO JOP/2011/0402A patent/JOP20110402B1/ar active
- 2011-12-30 MX MX2013007455A patent/MX350903B/es active IP Right Grant
- 2011-12-30 DK DK11810777.0T patent/DK2658870T3/en active
- 2011-12-30 ES ES11811633.4T patent/ES2690095T3/es active Active
- 2011-12-30 SG SG2013046651A patent/SG191211A1/en unknown
- 2011-12-30 HU HUE11810777A patent/HUE038535T2/hu unknown
- 2011-12-30 CA CA2822061A patent/CA2822061C/en active Active
- 2011-12-30 PL PL17189925T patent/PL3284754T3/pl unknown
- 2011-12-30 EA EA201390993A patent/EA029303B1/ru unknown
- 2011-12-30 DK DK11811633.4T patent/DK2658871T3/en active
- 2011-12-30 US US13/341,860 patent/US8362211B2/en active Active
- 2011-12-30 EP EP17189927.1A patent/EP3284755B1/en active Active
- 2011-12-30 SI SI201131939T patent/SI3284754T1/sl unknown
- 2011-12-30 SI SI201131534T patent/SI2658870T1/sl unknown
- 2011-12-30 ES ES17189925T patent/ES2841299T3/es active Active
- 2011-12-30 PT PT118116334T patent/PT2658871T/pt unknown
- 2011-12-30 MY MYPI2013002489A patent/MY160499A/en unknown
- 2011-12-30 SI SI201131541T patent/SI2658871T1/sl unknown
- 2011-12-30 EP EP17189925.5A patent/EP3284754B1/en active Active
- 2011-12-30 EA EA201791186A patent/EA201791186A1/ru unknown
- 2011-12-30 KR KR1020227034240A patent/KR102602640B1/ko active IP Right Grant
- 2011-12-30 KR KR1020207001665A patent/KR102294213B1/ko active IP Right Grant
- 2011-12-30 KR KR1020197002704A patent/KR102070326B1/ko active IP Right Grant
- 2011-12-30 GE GEAP201113177A patent/GEP20166493B/en unknown
- 2011-12-30 US US13/977,207 patent/US9102744B2/en active Active
- 2011-12-30 EP EP11811633.4A patent/EP2658871B1/en active Active
- 2011-12-30 CN CN202110630414.2A patent/CN113480649A/zh active Pending
- 2011-12-30 WO PCT/US2011/068235 patent/WO2012092612A1/en active Application Filing
- 2011-12-30 PE PE2013001487A patent/PE20140247A1/es active IP Right Grant
- 2011-12-30 RS RS20201556A patent/RS61280B1/sr unknown
- 2011-12-30 UY UY0001033850A patent/UY33850A/es not_active Application Discontinuation
- 2011-12-30 LT LTEP17189925.5T patent/LT3284754T/lt unknown
- 2011-12-30 PL PL11810777T patent/PL2658870T3/pl unknown
- 2011-12-30 LT LTEP11810777.0T patent/LT2658870T/lt unknown
- 2011-12-30 CN CN201710699217.XA patent/CN107365385A/zh active Pending
- 2011-12-30 KR KR1020217026369A patent/KR102451597B1/ko active IP Right Grant
- 2011-12-30 WO PCT/US2011/068244 patent/WO2012092616A1/en active Application Filing
- 2011-12-30 RS RS20180902A patent/RS57494B1/sr unknown
- 2011-12-30 ES ES11810777.0T patent/ES2674175T3/es active Active
- 2011-12-30 AU AU2011351921A patent/AU2011351921B2/en active Active
- 2011-12-30 EP EP20198444.0A patent/EP3789404A1/en active Pending
- 2011-12-30 LT LTEP11811633.4T patent/LT2658871T/lt unknown
- 2011-12-30 JP JP2013547713A patent/JP6148984B2/ja active Active
- 2011-12-30 PT PT118107770T patent/PT2658870T/pt unknown
- 2011-12-30 NZ NZ705848A patent/NZ705848A/en unknown
- 2011-12-30 KR KR1020137017570A patent/KR101945002B1/ko active IP Right Grant
- 2011-12-30 CN CN201180063232.6A patent/CN103282383B/zh active Active
- 2011-12-30 DK DK17189925.5T patent/DK3284754T3/da active
- 2011-12-30 PL PL11811633T patent/PL2658871T3/pl unknown
- 2011-12-30 HU HUE11811633A patent/HUE038727T2/hu unknown
- 2011-12-30 JP JP2013547710A patent/JP5843884B2/ja active Active
- 2011-12-30 BR BR112013017009-3A patent/BR112013017009B1/pt active IP Right Grant
- 2011-12-30 NZ NZ61227211A patent/NZ612272A/en unknown
- 2011-12-30 HU HUE17189925A patent/HUE052906T2/hu unknown
- 2011-12-30 EP EP20189000.1A patent/EP3798231A1/en not_active Withdrawn
- 2011-12-30 EP EP11810777.0A patent/EP2658870B1/en active Active
- 2011-12-30 RS RS20180859A patent/RS57526B1/sr unknown
- 2011-12-30 PT PT171899255T patent/PT3284754T/pt unknown
-
2012
- 2012-12-19 US US13/720,837 patent/US8926969B2/en active Active
- 2012-12-30 TR TR2018/08709T patent/TR201808709T4/tr unknown
-
2013
- 2013-06-16 IL IL226973A patent/IL226973A/en active IP Right Grant
- 2013-06-21 CR CR20130313A patent/CR20130313A/es unknown
- 2013-06-24 ZA ZA2013/04696A patent/ZA201304696B/en unknown
- 2013-06-25 MX MX2020012426A patent/MX2020012426A/es unknown
- 2013-06-27 MA MA36052A patent/MA34763B1/fr unknown
- 2013-07-18 CO CO13170417A patent/CO6761368A2/es active IP Right Grant
- 2013-07-29 EC ECSP13012794 patent/ECSP13012794A/es unknown
-
2014
- 2014-11-21 US US14/550,796 patent/US9790285B2/en active Active
-
2015
- 2015-06-29 US US14/754,592 patent/US9676869B2/en active Active
- 2015-09-02 JP JP2015172783A patent/JP6425635B2/ja active Active
- 2015-12-18 JP JP2015247967A patent/JP6425644B2/ja active Active
-
2017
- 2017-05-17 US US15/598,241 patent/US10336833B2/en active Active
- 2017-07-04 AU AU2017204571A patent/AU2017204571B2/en active Active
- 2017-07-24 JP JP2017143106A patent/JP6621447B2/ja active Active
- 2017-07-24 JP JP2017143107A patent/JP6563446B2/ja active Active
- 2017-09-13 US US15/703,833 patent/US10494444B2/en active Active
-
2018
- 2018-03-28 HK HK18104295.4A patent/HK1245284A1/zh unknown
- 2018-07-23 HR HRP20181176TT patent/HRP20181176T1/hr unknown
- 2018-07-24 CY CY20181100773T patent/CY1122161T1/el unknown
- 2018-08-01 HR HRP20181245TT patent/HRP20181245T1/hr unknown
- 2018-08-02 CY CY20181100806T patent/CY1122165T1/el unknown
- 2018-08-08 HK HK18110205.0A patent/HK1250735A1/zh unknown
-
2019
- 2019-05-14 US US16/412,297 patent/US20200031951A1/en not_active Abandoned
- 2019-07-24 JP JP2019136165A patent/JP6766233B2/ja active Active
- 2019-09-25 JP JP2019174782A patent/JP6840813B2/ja active Active
- 2019-10-17 US US16/656,401 patent/US11434304B2/en active Active
- 2019-11-13 AU AU2019264573A patent/AU2019264573B2/en active Active
-
2020
- 2020-09-16 JP JP2020155609A patent/JP7096301B2/ja active Active
- 2020-12-14 HR HRP20201996TT patent/HRP20201996T1/hr unknown
- 2020-12-21 CY CY20201101205T patent/CY1123739T1/el unknown
-
2021
- 2021-02-17 JP JP2021023741A patent/JP7315598B2/ja active Active
-
2022
- 2022-08-31 US US17/823,905 patent/US20230037373A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020012426A (es) | Anticuerpos anti-cd38. | |
MX350200B (es) | Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74. | |
PH12014501108A1 (en) | Anti-il-36r antibodies | |
PH12014502406A1 (en) | Anti-il-23p19 antibodies | |
MX340295B (es) | Anticuerpos monoclonales anti-c-met. | |
MX2019000046A (es) | Anticuerpos anti-il-23. | |
UA109464C2 (uk) | Спірооксіндольні антагоністи mdm2 | |
MY155950A (en) | Anti-cd40 antibodies | |
SG184310A1 (en) | Antibodies that bind human cd27 and uses thereof | |
MX347734B (es) | Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas. | |
AU2010233994A8 (en) | Bispecific anti-ErbB-3/anti-c-Met antibodies | |
EP3539988A3 (en) | Monoclonal antibodies against her2 | |
TN2012000161A1 (en) | Spiro-oxindole mdm2 antagonists | |
MX347893B (es) | Conjugados de farmaco y anticuerpo humano contra factor de tejido. | |
MX346375B (es) | Antagonistas de espiro-oxindol de mdm2. | |
TN2012000414A1 (en) | Forms of rifaximin and uses thereof | |
MX349004B (es) | Nuevos compuestos. | |
TN2013000265A1 (en) | Anti-cd38 antibodies | |
TN2014000207A1 (en) | Anti il-36r antibodies | |
TN2013000186A1 (en) | Anti-il-23 antibodies | |
TN2013000202A1 (en) | Spiro-oxindole mdm2 antagonists |